Patient Capital Management

QUARTERLY INVESTMENT REVIEW

Christina Malbon, CFA, Assistant Portfolio Manager

During the fourth quarter of 2024, the Patient Opportunity Trust (Class I) generated a total return of 8.52%. In comparison, the Fund's unmanaged benchmark, the S&P 500 Index, returned 2.41%.

Using a three-factor performance attribution model, allocation and selection effects contributed to the portfolio's outperformance, which were partially offset by interaction effects. **Sofi Technologies Inc. (SOFI)**, **United Airlines Holdings Inc. (UAL)**, **Peloton Interactive Inc. (PTON)**, **Energy Transfer LP (ET)**, and **Amazon.com Inc. (AMZN)** were the largest contributors to performance, while **CVS Health Corp. (CVS)**, **IAC Inc. (IAC)**, **Crocs Inc. (CROX)**, **Biogen Inc. (BIIB)**, and **Alibaba Group Holdings Inc. (BABA)** were the largest detractors.

Top Ten by Issuer as of 12/31/24

Name	% of Portfolio
Amazon.com, Inc.	6.7
QXO, Inc.	6.0
Alphabet Inc.	5.7
Citigroup Inc.	5.3
Energy Transfer LP	4.9
Meta Platforms, Inc.	4.3
Nvidia Corp.	4.2
General Motors Co.	4.0
Expedia Group, Inc.	3.8
Royalty Pharma plc	3.5
Total	**48.6%**

Relative to the index, the fund was overweight the Consumer Discretionary, Communication Services, Financials, Energy, and Health Care sectors on average during the quarter. With zero allocation to Real Estate, Utilities, Materials, and Consumer Staples, the fund was underweight these sectors along with the Information Technology, and Industrials sectors.

The portfolio added three positions: **Precigen Convertible Preferreds**, **Precigen Warrants**, and **Fidelity Wise Origin Bitcoin Fund (FBTC)** and eliminated four positions: **Fiserv Inc. (FI)**, **PureTech Health plc (PRTC LN)**, **Travel & Leisure (TNL)**, and **Western Alliance Bancorporation (WAL)**, during the quarter. The fund ended the quarter with 37 holdings where the top 10 stocks represented 48.6% of total assets compared to 37.3% for the index, highlighting the fund's meaningful active share of 94.2%.

Average Annual Total Returns and Expenses (%) as of 12/31/24

	Without Sales Charges						With Maximum Sales Charges						
	QTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception*	QTD	1Yr	3 Yr	5 Yr	10Yr	Inception*	Inception Date
Class A (LGOAX)	8.45	26.34	3.99	8.57	8.69	14.85	2.20	19.08	1.96	7.29	8.05	14.42	2/3/09
Class C (LMOPX)	8.24	25.40	3.18	7.73	7.87	6.69	7.24	24.40	3.18	7.73	7.87	6.69	12/30/99
Class FI (LMOFX)	8.42	26.27	3.91	8.48	8.62	6.85	8.42	26.27	3.91	8.48	8.62	6.85	2/13/04
Class I (LMNOX)	8.52	26.71	4.26	8.84	8.97	7.75	8.52	26.71	4.26	8.84	8.97	7.75	6/26/00
Class IS (MVISX)	8.51	26.77	4.32	8.91	-	6.65	8.51	26.77	4.32	8.91	–	6.65	8/22/18
Class R (LMORX)	8.38	26.01	3.72	8.28	8.38	5.82	8.38	26.01	3.72	8.28	8.38	5.82	12/28/06
S&P 500	2.41	25.02	8.94	14.53	13.10	7.71	2.41	25.02	8.94	14.53	13.10	7.71	

*S&P 500 since inception return represented from 12/30/99, the Fund's oldest share class.

Gross (Net) Expenses (%): Class A 2.12 (2.11); Class C 2.88 (2.87); Class FI 2.17 (2.16); Class I 1.88 (1.85); Class IS 1.78 (1.77); Class R 2.38 (2.37).

***Performance shown represents past performance and is no guarantee of future results.** Current performance may be higher or lower than the performance shown. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. With respect to Class I only, the Adviser has agreed to waive fees and/or reimburse operating expenses such that the previously described annual operating expenses, plus intermediary servicing fees and other class-specific expenses, will not exceed 0.93%. Investment return and principal value will fluctuate so shares, when redeemed, may be worth more or less than the original cost. Class A shares have a maximum front-end sales charge of 5.75%. Class C shares have a one-year contingent deferred sales charge (CDSC) of 1.0%. If sales charges were included, performance shown would be lower. Total returns assume the reinvestment of all distributions at net asset value and the deduction of all Fund expenses. Total return figures are based on the NAV per share applied to shareholder subscriptions and redemptions, which may differ from the NAV per share disclosed in Fund shareholder reports. Performance would have been lower if fees had not been waived in various periods. YTD is calculated from January 1 of the reporting year. All classes of shares may not be available to all investors or through all distribution channels. For the most recent month-end information, please call 800-655-0324 or visit patientcapitalmanagement.com/opportunity-trust.*

Portfolio Review

While history doesn't repeat itself, it often rhymes. The fourth quarter of 2024 looked much like the fourth quarter of 2023 and for similar reasons. 2023 benefited from a renewed belief in a soft-landing, as did 2024 which was sparked by the election of Donald Trump as the next President and a belief that would bring growth-oriented policies and lower regulation.

The top performers in the fourth quarter were once again Financials and Travel names. We've been over-indexed to them since the pandemic, which has served us well. We strategically added to certain financial names like **Sofi Technologies (SOFI)** and **Coinbase Global Inc. (COIN)** during the year. Both companies rebounded strongly in the fourth quarter. We believe Coinbase is building the platform for the crypto ecosystem. Certain recent advances (wallet, base improvements, USD Coin) could cause an adoption tipping point. We like that Coinbase continues to widen its moat by persistently investing in innovation.

We've owned Sofi since its de-SPAC in 2020. The company is early in its life cycle with a very large total addressable market (TAM). As with most early-stage companies, the stock can be volatile, and we aim to monetize that volatility. We added to the stock in the $6s as we believed the combination of a proven management team, strong fundamentals, lower interest rates and reaching profitability weren't appropriately discounted. The stock advanced more than 180% from the lows into year-end highs as the company beat expectations and announced its Lending Platform business (fee-for-service with no credit risk).

Despite years of strong fundamentals from our travel names, 2024 seemed to be the year that other investors started to believe in travel strength durability. Demand for travel has continued to be strong despite concerns around consumer health. According to IATA (International Air Transport Association) global air passenger travel is still below the pre-COVID implied trend path despite reaching a new all time-high this year.

As reversion to the mean continues, we believe our high-quality names like **Delta Air Lines (DAL)**, **United Airlines Holdings (UAL)**, **Expedia Group Inc. (EXPE)**, and **Norwegian Cruise Line (NCLH)** will continue to benefit.

Finally, we took the opportunity to reinvest some of our winnings into laggards particularly in the healthcare and energy space. Names like **Biogen Inc. (BIIB)**, and **CVS Health Corp. (CVS)** traded at decade low prices creating attractive opportunities to add exposure while high-quality companies like **Royalty Pharma (RPRX)** traded roughly sideways allowing us to add exposure to a more defensive name.

New and Eliminated

This quarter we entered three new positions, while exiting four positions. We participated in a PIPE (private investment in public entity) deal with **Precigen Inc. (PGEN)** at the end of the fourth quarter resulting in new positions in a perpetual convertible preferred as well as warrants. Precigen is an early-stage biopharmaceutical company focused on next generation cell and gene therapies. The company's PRGN-2012 program in recurrent respiratory papillomatosis (RRP) has the potential to be the first-in-class "off-the-shelf" immunotherapy in a patient population with limited options. The company submitted their biologics license application (BLA) for PRGN-2012 on December 30th with a request for a priority review setting the clock for a decision by mid-2025. The additional capital raise is expected to fund the company's operations well into 2026 and help fund the launch of this all-important drug in an orphan designation. The company is run by Dr. Helen Sabzevari, who has extensive expertise in research and development of immunotherapy-based therapeutics, having founded and served as Chief Scientific Officer of Compass Therapeutics. She has driven amazing clinical progress at PGEN over the past few years and we believe that PRGN-2012 is well positioned to be a best-in-class therapeutic for RRP.

In the quarter we entered a position in Bitcoin via the **Fidelity Wise Origin Bitcoin Fund (FBTC)**. We see Bitcoin as an attractive diversifier to the fund. We continue to be optimistic over the long-term. As Bitcoin becomes more easily accessible, demand should increase, while the supply of Bitcoin will continue to be limited at 21M. We continue to think of Bitcoin as digital gold with a materially lower market cap of $1.9T vs $17.9T for Gold.

We exited **PureTech Health PLC (PRTC LN)**, **Fiserv Inc. (FI)**, **Travel & Leisure (TNL)**, and **Western Alliance Bancorporation (WAL)** in the quarter to redeploy investments into new ideas.

Top Contributors & Top Detractors

Top Contributors	Ticker	Bps Contribution
Sofi Technologies Inc.	SOFI	225
United Airline Holdings Inc.	UAL	194
Peloton Interactive Inc.	PTON	109
Energy Transfer LP	ET	107
Amazon.com Inc.	AMZN	106

Top Detractors	Ticker	Bps Contribution
CVS Health Corp.	CVS	-94
IAC Inc.	IAC	-91
Crocs Inc.	CROX	-70
Biogen Inc.	BIIB	-68
Alibaba Group Holdings Ltd	BABA	-66

Contribution illustrated above is provided gross of fees and includes cash

Top Contributors

- **Sofi Technologies Inc. (SOFI)** was a standout in the quarter, climbing 95% and up 156% from the intra-day lows in June. The company benefited from Fed rate cuts and the market's growing optimism that the economy will avoid a recession. The company continues to grow its customer count while successfully cross selling into their loans and financial service products. In the quarter, we saw the company take on a new revenue stream by originating loans for third parties, creating an attractive balance sheet-light revenue source, helping improve return on equity and margins. Sofi is early in its life cycle, currently being a small player in a very large total addressable market (TAM). With their strong management team, we believe the company will continue to deliver on their guidance of strong growth and expanding margins.
- **United Airlines Holdings (UAL)** had a strong fourth quarter, gaining 70.2% in the period. The company benefitted from continued strong demand that surprised the market as well as the initiation of a buyback program, the first since COVID. There continues to be strong travel demand from both retail and business travelers. According to the International Air Transport Association (IATA), global air passenger travel is still below the pre-COVID implied trend path despite reaching a new all-time high this year. United's focus on the customer over the last few years has led to strong improvement in net promoter scores (NPS) which should continue to flow through the model via better TRASM (total revenue per available seat mile) and higher cash flows and earnings. As of today, United alone accounts for ~30% of the overall industry's profits. We expect this market share to grow and be defensible as we transition to an environment where customer service becomes the differentiating factor, and scale provides unparalleled ability to reinvest in the customer experience.
- **Peloton Interactive Inc. (PTON)** took off in the fourth quarter, climbing 85.8% and up 202.1% from the lows in August. Peloton is the posterchild of a pandemic beneficiary taking advantage of lockdowns to sell people exercise equipment they could use at home. The normalization process from this heightened level of demand has pressured the stock for the last few years. However, in 2024 the company made a material pivot from a growth focus to a margin and cash flow focus. With this renewed focus on managing profitability the company successfully moved EBITDA into positive territory, improved their inventory position, and successfully refinanced their debt. The company also announced a new CEO in October, the third one in as many years, bringing a new set of eyes to reinvigorate the company. We continue to believe the value of the business lives in the high-margin, sticky subscription piece of the business.

Top Detractors

- **CVS Health Corp. (CVS)** struggled throughout the year following a number of disappointments related to their Medicare Advantage business. While this had a negative impact on the near-term financials, the issues are well understood, and changes are already being made for the 2025 program. We see a clear pathway to improving margins throughout 2025 in all areas of the business. Furthermore, the company has upgraded their management team promoting David Joyner to CEO and hiring former UnitedHealth Group executive Steven Nelson to run the managed care business. On a longer-term basis, we continue to think CVS has an attractive combination of assets owning a healthcare benefits business (Aetna), a pharmacy-benefits manager (Caremark), an in-home evaluation business (Signify Health) and in-home primary care business (Oak Street Health) supporting the industry transition to a value-based care model. As the company works to implement the turnaround, the company has an attractive dividend yield of 5.8%.

- **IAC Inc. (**IAC) declined in the fourth quarter following the announcement that the company is considering spinning out its remaining ownership of Angi Inc. (ANGI) to shareholders. The company is focused on slimming down IAC and building cash in order to take advantage of attractive M&A opportunities. This is a strategy the company has employed for years and one which has created a lot of shareholder value. The company trades at an extremely attractive valuation as the company's publicly traded ownership stakes in Angi Inc. (ANGI) and MGM Resorts International (MGM) and its corporate cash balance alone account for 107% of the current market cap. This means there is no value currently being attributed to their private holdings Meredith, Vivian Health, Care.com, and Turo. Many of the private assets are household names. While conglomerates do not always receive the valuation credit they deserve, IAC has a history of spinning-out assets and capturing value for their shareholders. We have no doubt that will continue to be the case.
- **Crocs Inc. (CROX)** declined in the quarter following another Heydudes disappointment with implied growth for 4Q below expectations. The company has been attempting to turn around the Heydudes brand which it purchased in 2022 but has been suffering from market saturation and still limited brand awareness. In April, the company announced the appointment of Terence Reilly as EVP and President of Heydudes. Terence is best known for his time at Stanley where he reshaped the insulated drinkware brand into a current cultural item. The company is hoping he can bring some of this magic to the Heydudes brand. Despite the Heydudes disappointment, the core brand continues to deliver, growing in the high-single-digits with margin expansion. Overall, we view the child piece of the core Crocs product as a consumer staple and believe people are underappreciating its durability. The company continues to repurchase its stock with an outstanding buyback program representing 8.5% of shares outstanding.

Performance Attribution Analysis	Patient Opportunity Trust Weight	Patient Opportunity Trust Return	S&P 500 Weight	S&P 500 Return	Management Effect Allocation	Management Effect Selection	Management Effect Interaction	Management Effect Total
Equity- Long Positions	**108.37**	**7.95**	**100.00**	**2.41**	**3.12**	**5.43**	**-2.63**	**5.93**
Communication Services	14.45	-1.96	9.04	8.87	0.33	-0.99	-0.65	-1.31
Consumer Discretionary	33.44	7.30	10.60	14.25	2.68	-0.74	-1.50	0.44
Consumer Staples	0.00	0.00	5.67	-3.26	0.34	0.20	-0.20	0.34
Limited Partnership	0.13	-37.53	0.00	0.00	-0.00	0.00	-0.07	-0.07
Energy	11.17	6.79	3.34	-2.44	-0.47	0.32	0.82	0.67
Financials	18.59	24.16	13.44	7.09	0.25	2.18	0.77	3.20
Health Care	13.49	-10.57	10.74	-10.30	-0.36	0.00	0.02	-0.33
Industrials	6.50	44.52	8.46	-2.27	0.09	3.62	-0.91	2.80
Information Technology	10.34	4.62	32.00	4.84	-0.56	0.22	-0.25	-0.59
Materials	0.00	0.00	2.09	-12.42	0.34	0.28	-0.28	0.34
Real Estate	0.00	0.00	2.21	-7.94	0.25	0.19	-0.19	0.25
Utilities	0.00	0.00	2.42	-5.51	0.21	0.14	-0.14	0.21
Cryptocurrency	0.25	-2.03	0.00	0.00	0.02	0.00	-0.03	0.00
Cash*	-8.37	-0.02	0.00	0.00	0.26	0.00	0.02	0.28
Total	**100.00**	**8.62**	**100.00**	**2.41**	**3.38**	**5.43**	**-2.61**	**6.21**

*Returns are gross of fees.

Market Proxy is S&P 500. Returns greater than 1 year are annualized. Source: Bloomberg and Patient Capital Management.

The data provided is from APX and Patient Capital Management, LLC and is believed to be reliable, but is not guaranteed as to its timeliness or accuracy. Percentages and returns may not sum to 100% due to rounding effects. A three-factor attribution consists of the allocation effect, selection effect, and the interaction effect, which sum to the portfolio's performance relative to the benchmark.

- **Allocation.** The allocation effect represents the portion of the portfolio's excess return attributable to differences in sector weights between the portfolio and the benchmark index.
- **Selection.** The selection effect represents the portion of the portfolio's excess return attributable to differences in the weights of individual securities within each sector between the portfolio and the benchmark index.
- **Interaction.** Most complex and sometimes counterintuitive, the interaction effect represents the portion of the portfolio's excess return attributable to combining sector allocation decisions with security selection decisions, and is often thought of as measuring the accuracy of manager's convictions.

Please note that the methodology used by our independent third-party attribution software vendor will at times present sector allocation effects that are counterintuitive. For example, the software may calculate a negative sector effect even when the portfolio, on a weighted average basis for the period, overweight an outperforming sector. Under the vendor's methodology, allocation effects in recent months may overwhelm the allocation effects from earlier in the period, particularly over longer time frames.

Returns illustrated above are provided net of fees and include cash. Total portfolio return figures provided above reflect the sum of the returns of the holdings in the representative account portfolio due to price movements and dividend payments or other sources of income.

Patient Capital Management

CONTACT

Advisor Services
443.652.4225 | info@patientcm.com

patientcapitalmanagement.com/opportunity-trust

PATIENT CAPITAL MANAGEMENT

Patient Capital Management LLC is an SEC registered investment advisor founded in 2020 by Samantha McLemore, majority owner and Chief Investment Officer. Formerly operating with Miller Value Partners, Patient Capital acquired the Opportunity Equity business in May 2023 in a transaction completing Bill Miller's succession plan. As of 12/31/24, Patient Capital operates independently managing $2.1B in assets featuring opportunistic, long-term, value-oriented equity strategies. The Firm is supported by a team of 10 professionals. Bill Miller remains a minority owner and adviser.

Effective 8/21/23, the Opportunity Trust changed its name to the Patient Opportunity Trust.

The **S&P 500 Index** is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. **EBITDA** is earnings before interest, taxes, depreciation and amortization and is a calculation of a company's financial health. **Earnings per share (EPS**) is a company's net income subtracted by preferred dividends and then divided by the average number of common shares outstanding. **Basis point (Bps)** is one hundredth of one percent. **Dividend yield** is the ratio of a company's annual dividend compared to its share price.

Earnings growth is not representative of the Fund's future performance.

Equity securities are subject to price fluctuation and possible loss of principal. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. The Fund may focus its investments in certain regions or industries, increasing its vulnerability to market volatility. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. Derivatives, such as options and futures, can be illiquid, may disproportionately increase losses, and have a potentially large impact on Fund performance. The manager's investment style may become out of favor and/or the manager's selection process may prove incorrect, which may have a negative impact on the Fund's performance. Short selling is a speculative strategy. Unlike the possible loss on a security that is purchased, there is no limit on the amount of loss on an appreciating security that is sold short.

The views expressed are those of the portfolio managers as of the date indicated, are subject to change, and may differ from the views of other portfolio managers or the firm as a whole. These opinions are not intended to be a forecast of future events, a guarantee of future results, or investment advice. All data referenced are from sources deemed to be reliable but cannot be guaranteed. Discussions of individual securities are intended to inform shareholders as to the basis (in whole or in part) for previously made decisions by a portfolio manager to buy, sell or hold a security in a portfolio. References to specific securities are not intended and should not be relied upon as the basis for anyone to buy, sell or hold any security. Portfolio holdings and sector allocations may not be representative of the portfolio manager's current or future investment and are subject to change at any time.

The Fund obtains indirect exposure to Bitcoin through its holding of the Fidelity Wise Origin Bitcoin Trust (FBTC). Bitcoin and other cryptocurrencies are a relatively new asset class and are subject to unique and substantial risks.

The Patient Opportunity Trust is distributed by Quasar Distributors, LLC.

Before investing, carefully consider a Fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus if available, which is available at patientcapitalmanagement.com/opportunity-trust. Please read it carefully.